Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581124 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
A Phase 1 study, sponsored by Akros Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02581124 is a Phase 1 study that has completed, run by Akros Pharma. The registered enrollment target is 10 participants.
The verdict
NCT02581124, a Phase 1 study, has completed, sponsored by Akros Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Study to evaluate the effect of lapatinib, a breast cancer resistance protein (BCRP) inhibitor, on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety and tolerability of JTZ-951 when administered alone and one hour after the administration of lapatinib.
Interventions
- DRUG Lapatinib
- DRUG JTZ-951
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02581124
The ClinicalTrials.gov registry entry for NCT02581124 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akros Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lapatinib is the first listed.
NCT02581124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02581124 about?
NCT02581124 is a clinical study titled "Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease". Study to evaluate the effect of lapatinib, a breast cancer resistance protein (BCRP) inhibitor, on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety and tolerability of JTZ-951 when administered alone and one hour after the administration of lapatinib.
What is the current status of trial NCT02581124?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2015-10. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02581124?
The interventions under investigation include: Lapatinib (DRUG), JTZ-951 (DRUG).
Who is sponsoring clinical trial NCT02581124?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.